[Antiplatelet drugs and intraoperative hemorrhage].

Abstract

Antiplatelet drugs and intraoperative haemorrhage Current literature demonstrates that there is less risk involved in maintaining anti-aggregant therapy (which might imply to transfuse more the patients), than in stopping it, which then increases dangerously the risk of coronary thrombosis. Aspirin, as a secondary preventive drug, should not be interrupted. Clopidogrel is essential for protection against thrombosis in areas where the endothelium is not intact. Unless there is a high hemorrhagic risk in closed cavities (intracranial surgery), clopidogrel should not be interrupted. Furthermore, any surgical intervention increasing the coagulability of the platelets, it seems particularly dangerous to stop such medication perioperatively.

• Authors: Pierres Guy Chassot, Alain Delabays, Patrick Ravussin, Donat R Spahn
• Journal: Revue medicale suisse (Rev Med Suisse) Vol. 2 Issue 88 Pg. 2684-7 (Nov 22 2006) ISSN: 1660-9379 [Print] Switzerland
• Vernacular Title: Antiplaquettaires et hemorragie peropératoire.
• PMID: 17265808 (Publication Type: Journal Article, Review)

Chemical References

• Platelet Aggregation Inhibitors
• Platelet Glycoprotein GPIIb-IIIa Complex
• Clopidogrel
• Ticlopidine
• Aspirin

Topics

• Algorithms
• Aspirin (therapeutic use)
• Blood Loss, Surgical (physiopathology)
• Clopidogrel
• Coronary Thrombosis (prevention & control)
• Drug Therapy, Combination
• Humans
• Intraoperative Period
• Platelet Aggregation Inhibitors (therapeutic use)
• Platelet Glycoprotein GPIIb-IIIa Complex (antagonists & inhibitors)
• Risk Assessment
• Ticlopidine (analogs & derivatives, therapeutic use)